Mavenclad key to Merck KGaA's growth in impressive year

5 March 2020

The financial results for the latest quarter and 2019 as a whole made for satisfying reading for shareholders of Germany’s Merck KGaA (MRK: DE).

Group sales for the fourth quarter of the year were 4.38 billion euros ($4.9 billion), up 13% on the same period of 2018, while the total 2019 figure was 16.15 billion euros, a rise of 9%.

The last quarter saw a 27% rise in the company’s key performance indicator of earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for special items. This reached 1.21 billion euros, beating analysts’ expectations, while for the year the same measure was up 15% at 4.01 billion euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK